Labeling and Packaging Errors Highlighted in IMP Supply Chain Audits

Posted on August 31, 2025 By digi

Published on 26/12/2025

Why Labeling and Packaging Errors in IMP Supply Chains Lead to Audit Findings

Table of Contents

Toggle

Introduction: The Critical Role of Labeling and Packaging

Accurate labeling and compliant packaging of Investigational Medicinal Products (IMPs) are essential to ensure patient safety, maintain blinding, and meet regulatory requirements. Errors in labeling or packaging can compromise randomization, mislead investigators, or even endanger trial participants. Regulatory agencies such as the FDA, EMA, and MHRA closely scrutinize IMP supply chains, and deficiencies in labeling or packaging are among the most common audit findings.

These errors typically include missing or incorrect information on labels, non-compliance with language requirements, inadequate packaging for stability, or deviations from blinding procedures. Such issues are categorized as major or critical deficiencies during inspections, often delaying trial progression or regulatory submissions.

See also  Training Record Gaps: Common Site Audit Observations

Regulatory Expectations for IMP Labeling and Packaging

Authorities define strict requirements for labeling and packaging compliance:

• Labels must contain protocol number, batch/lot number, storage conditions, expiry dates, and dosing instructions.
• Label content must comply with ICH GCP, national legislation, and

Continue Reading

trial-specific requirements.

Translations must be accurate and verified for local regulatory acceptance.

Packaging must maintain product stability and integrity throughout the supply chain.

Blinding procedures must be preserved and documented in line with trial design.

The NIHR Be Part of Research portal emphasizes the significance of accurate labeling and packaging in maintaining trial integrity and ensuring patient safety.

Common Audit Findings on Labeling and Packaging Errors

1. Incorrect or Missing Information

Auditors frequently note absent protocol numbers, wrong expiry dates, or incomplete storage instructions on IMP labels.

2. Language Non-Compliance

Audit reports often cite untranslated or incorrectly translated labels, leading to regulatory non-compliance.

3. Packaging Integrity Failures

Inspectors regularly observe inadequate packaging, risking product stability during shipment or storage.

4. Blinding Failures Due to Labeling

Incorrectly designed labels sometimes reveal treatment allocation, compromising blinding and trial validity.

Case Study: EMA Audit on IMP Labeling

In a Phase II cardiovascular study, EMA inspectors found that several IMP labels were missing storage condition instructions. Additionally, packaging at one depot failed to maintain required 2–8°C stability during transport. The findings were deemed major, requiring corrective action before further IMP shipments were released.

Root Causes of Labeling and Packaging Errors

Root cause investigations of audit findings typically identify:

• Lack of SOPs for label design, review, and approval processes.
• Inadequate translation verification for multinational studies.
• Poor sponsor oversight of CRO and vendor packaging facilities.
• Failure to validate packaging for stability under anticipated conditions.
• Weak communication between supply chain, QA, and clinical operations teams.

Corrective and Preventive Actions (CAPA)

Corrective Actions

• Re-label affected IMP batches with corrected information and regulatory approval.
• Update TMF with complete labeling and packaging records, including translations.
• Repackage IMPs to maintain blinding and stability as required by the protocol.

Preventive Actions

• Develop SOPs covering label creation, translations, and packaging validation.
• Conduct QA review and approval of all labeling and packaging materials before release.
• Implement vendor qualification and auditing processes for packaging facilities.
• Verify label accuracy during monitoring visits and sponsor audits.
• Integrate labeling and packaging oversight into risk-based monitoring strategies.

Sample IMP Labeling and Packaging Log

The following dummy table demonstrates how labeling and packaging compliance can be tracked:

Best Practices for Preventing Labeling and Packaging Findings

To reduce audit risks, sponsors and sites should adopt these practices:

• Ensure all labels contain complete, accurate, and regulatory-compliant information.
• Verify translations for accuracy and maintain documented approvals.
• Validate packaging to confirm stability under all anticipated conditions.
• Maintain labeling and packaging documentation in the TMF for inspection readiness.
• Audit vendors and depots regularly to verify compliance with labeling/packaging requirements.

Conclusion: Enhancing Compliance in Labeling and Packaging Oversight

Labeling and packaging errors remain a recurring regulatory audit finding because they directly impact product safety, trial validity, and participant protection. Regulators expect sponsors and CROs to maintain complete oversight of IMP labeling and packaging processes.

By enforcing SOP-driven processes, validating packaging systems, and conducting proactive oversight, sponsors can minimize audit risks and maintain regulatory compliance. Effective labeling and packaging practices ensure inspection readiness while safeguarding trial quality.

For more information, visit the ANZCTR Clinical Trials Registry, which emphasizes transparency and quality in clinical trial supply chains.